$SCYX News

SCYNEXIS Announces 1-For-8 Reverse Stock Split, Effective May 29

SCYNEXIS Q1 EPS $(0.42) Misses $(0.12) Estimate

SCYNEXIS Announces Prospectus Of 87M Shares By Selling Stockholders

SCYNEXIS INC (NASDAQ:SCYX) Combines Minervini Trend Template with High-Growth Momentum Fundamentals

SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics - Slideshow

SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript

SCYNEXIS Announces $40M Private Placement, Warrants May Add $52M To Proceeds

SCYNEXIS Agrees With Poxel To Acquire PXL-770; $8M Upfront, Up To $188M Milestones

SCYNEXIS Says On March 15, 2026 Co Received FDA Orphan Drug Designation For Brexafemme (Triterpenoid Antifungal) For Treatment Of Invasive Candidiasis

SCYNEXIS Q4 Earnings Assessment

SCYNEXIS Q4 EPS $0.25 Beats $0.13 Estimate, Sales $18.646M Beat $8.100M Estimate

SCYNEXIS Says First Participants Dosed In Phase 1 SAD And MAD Trial Evaluating IV Of Second-Gen Triterpenoid Antifungal Therapy, SCY-247; Trial Results Expected In 2026

SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)

SCYNEXIS Announces Upcoming Presentations Highlighting Data On Second-Gen Fungerp Drug Candidate, SCY-247, At 2026 IMARI

SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247

SCYNEXIS Granted FDA's Qualified Infectious Disease Product, Fast Track Designations For Second-Generation Triterpenoid Antifungal Therapy SCY-247

SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

SCYNEXIS Receives Nasdaq Extension To Regain Bid Price Compliance By June 15, 2026

Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections

SCYNEXIS Secures 5-Year $7M Annual Federal Grant To Advance Next-Generation Antifungal Therapies